SSKN Combination Therapy Delivers Superior Results in Largest Vitiligo Study to Date

Peer-Reviewed Study Reveals Unmatched Efficacy and Safety for STRATA’s Excimer Laser Plus JAK Inhibitors

STRATA Skin Sciences (NASDAQ: SSKN) is drawing renewed clinical attention after the release of a robust peer-reviewed publication, spotlighting a combination therapy that pairs its well-established Excimer Laser with oral JAK inhibitors for the treatment of vitiligo. This randomized, controlled multicenter study—enrolling 251 adult patients—demonstrated response rates and safety profiles previously unseen in single-drug or standard therapies. The results, published in the International Journal of Dermatology, position SSKN’s personalized approach as a validated solution in managing this challenging autoimmune skin condition.

Key Clinical Findings: Larger Patient Base, Durable Repigmentation, Minimal Relapse

What sets this trial apart is not just its sample size, but its clear-cut findings. Patients who received the Excimer Laser plus JAK inhibitor combination achieved more rapid and lasting skin repigmentation than those treated with monotherapies—while maintaining excellent safety. Importantly, the large population size gives added weight and statistical power to the results, offering clinicians and payers new confidence in the treatment’s effectiveness.

The company’s leadership emphasizes that this level of efficacy is remarkable, particularly given that STRATA’s Excimer technology has already seen two decades of clinical use and is supported by over 400 publications.

Clinical Evidence Builds Case for Broader Adoption and Reimbursement

With a 20-year history of published clinical data, the Excimer Laser stands out as a cornerstone treatment not only for vitiligo but also for other inflammatory and autoimmune skin diseases like psoriasis, atopic dermatitis, and alopecia areata. The current study’s results directly support STRATA’s push for expanded reimbursement—meaning the therapy could soon be more accessible to a broader patient population, if payers recognize the enhanced value of combination regimens.

STRATA CEO Dr. Dolev Rafaeli highlighted how the therapy's customization—the duration of laser exposure and drug dosing—represents a true personalized medicine approach, further appealing to practitioners seeking durable outcomes with low side effect risk.

Outlook: Next Steps in Clinical Integration and Insurance Access

As the medical community increasingly shifts towards tailored dermatologic care, SSKN’s excimer platform combined with systemic therapies like JAK inhibitors could mark a pivotal shift in the vitiligo treatment landscape. STRATA’s management indicated they are actively engaging with regulators, aiming to achieve expanded reimbursement as early as 2026.

For investors and clinicians, the key takeaway is clear: this peer-reviewed data gives SSKN new validation, positioning its technology at the forefront of personalized, evidence-backed dermatology solutions. While clinical adoption will depend on further payer decisions and market awareness, these results may set the stage for broader insurance coverage and higher in-office use of SSKN’s unique combination therapy.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI